Jounce Therapeutics Inc. [NASDAQ: JNCE] gained 40.57% or 0.43 points to close at $1.49 with a heavy trading volume of 29090553 shares. The company report on March 14, 2023 that Jounce Therapeutics Confirms Receipt of Unsolicited Proposal from Concentra Biosciences.
From Robots to Self-Driving Cars: 5 AI Stocks to Consider for Your Portfolio
The artificial intelligence (AI) revolution is already here and it's about to change everything we know about everything. With the global market for AI projected to grow from $137 billion in 2022 to over $1.81 trillion by 2030, there's never been a better time to invest in this burgeoning industry. That's why we've compiled a list of the Top 5 AI Stocks to Buy for 2023. These companies are at the forefront of the AI revolution, and have the potential to deliver huge returns to investors like you.
Get our free report, "Top 5 AI Stocks to Buy for 2023".
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION.
It opened the trading session at $1.46, the shares rose to $1.64 and dropped to $1.43, the range by which the price of stock traded the whole day. The daily chart for JNCE points out that the company has recorded -52.70% loss over the past six months. However, it is still -156.9% lower than its most recent low trading price.
If we look at the average trading volume of 2.51M shares, JNCE reached to a volume of 29090553 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here is what top equities market gurus are saying about Jounce Therapeutics Inc. [JNCE]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for JNCE shares is $3.33 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on JNCE stock is a recommendation set at 2.70. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Robert W. Baird have made an estimate for Jounce Therapeutics Inc. shares, keeping their opinion on the stock as Neutral, with their previous recommendation back on May 11, 2022. While these analysts kept the previous recommendation, Raymond James raised their target price from $15 to $20. The new note on the price target was released on May 06, 2022, representing the official price target for Jounce Therapeutics Inc. stock. Previously, the target price had yet another raise to $17, while SMBC Nikko analysts kept a Outperform rating on JNCE stock.
The Average True Range (ATR) for Jounce Therapeutics Inc. is set at 0.15 The Price to Book ratio for the last quarter was 0.60, with the Price to Cash per share for the same quarter was set at 3.45.
Trading performance analysis for JNCE stock
Jounce Therapeutics Inc. [JNCE] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 39.91. With this latest performance, JNCE shares gained by 34.23% in over the last four-week period, additionally sinking by -52.70% over the last 6 months – not to mention a drop of -78.84% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for JNCE stock in for the last two-week period is set at 70.02, with the RSI for the last a single of trading hit 75.95, and the three-weeks RSI is set at 65.10 for Jounce Therapeutics Inc. [JNCE]. The present Moving Average for the last 50 days of trading for this stock 1.1327, while it was recorded at 1.0817 for the last single week of trading, and 2.2444 for the last 200 days.
Jounce Therapeutics Inc. [JNCE]: A deeper dive into fundamental analysis
Operating Margin for any stock indicates how profitable investing would be, and Jounce Therapeutics Inc. [JNCE] shares currently have an operating margin of -63.71 and a Gross Margin at +97.45. Jounce Therapeutics Inc.’s Net Margin is presently recorded at -62.10.
Return on Equity for this stock declined to -25.03, with Return on Assets sitting at -21.89.
Jounce Therapeutics Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 8.40 and a Current Ratio set at 8.40.
An analysis of insider ownership at Jounce Therapeutics Inc. [JNCE]
There are presently around $52 million, or 82.50% of JNCE stock, in the hands of institutional investors. The top three institutional holders of JNCE stocks are: RTW INVESTMENTS, LP with ownership of 5,106,341, which is approximately 0% of the company’s market cap and around 0.30% of the total institutional ownership; DEEP TRACK CAPITAL, LP, holding 4,259,653 shares of the stock with an approximate value of $6.35 million in JNCE stocks shares; and COWEN AND COMPANY, LLC, currently with $5.43 million in JNCE stock with ownership of nearly 0% of the company’s market capitalization.
37 institutional holders increased their position in Jounce Therapeutics Inc. [NASDAQ:JNCE] by around 6,633,094 shares. Additionally, 55 investors decreased positions by around 13,825,404 shares, while 21 investors held positions by with 14,714,247 shares. The mentioned changes placed institutional holdings at 35,172,745 shares, according to the latest SEC report filing. JNCE stock had 12 new institutional investments in for a total of 2,086,567 shares, while 24 institutional investors sold positions of 5,723,874 shares during the same period.